Healthcare Services

Increasing Cancer Prevalence Fueling The Growth Of The Market Due To Rising Demand For Precision Diagnostics Is Supporting Development Across The NGS Oncology Market

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The NGS Oncology Market?

The ngs oncology market size has experienced substantial growth in recent years. It is projected to expand from $19.33 billion in 2025 to $21.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.4%. This historic growth can be attributed to several factors including decreasing sequencing costs, a rise in global cancer prevalence, increased funding for oncology research, the early adoption of targeted therapies, and the growth of genomic research initiatives.

The ngs oncology market size is projected to experience substantial growth in the next few years. It is expected to reach $32.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. The expansion during the forecast period is attributable to the broadening of precision oncology programs, a rising demand for personalized cancer treatment, an increase in approvals for ngs-based diagnostics, advancements in bioinformatics analytics, and the integration of ngs into clinical guidelines. Major developments anticipated in this period include the wider use of comprehensive tumor profiling, the increasing adoption of liquid biopsy NGS, an enhanced clinical utility of multi-gene panels, the incorporation of NGS into routine oncology diagnostics, and a growing demand for faster turnaround sequencing workflows.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

Which Growth Drivers Are Expected To Support The NGS Oncology Market Forward?

An increasing incidence of cancer is anticipated to fuel the expansion of the NGS oncology market. This disease involves the uncontrolled growth of abnormal cells that can infiltrate various body parts, disrupting normal physiological functions. This surge in cancer cases is largely attributed to an aging populace, overall population expansion, and heightened exposure to risk factors including tobacco consumption, alcohol intake, obesity, and atmospheric pollution. NGS oncology plays a crucial role in public health and patient care by facilitating early detection, accurate diagnosis, and tailored treatment through comprehensive genetic profiling of tumors. For example, data released by the American Cancer Society, a US-based non-profit organization, in January 2024 indicates that the United States is expected to record 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, an increase from 1,958,310 cases and 609,820 deaths in 2023. Consequently, the increasing occurrence of cancer is a key factor propelling the expansion of the NGS oncology market.

How Is The NGS Oncology Market Structured Across Different Market Segments?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

Which Trends Are Guiding The Development Of The NGS Oncology Market?

Leading companies in the next-generation sequencing data analysis market are concentrating on developing advanced secondary analysis bioinformatics software. Their aim is to enable quicker and more precise identification of genetic variants for both research and clinical applications. Secondary analysis bioinformatics software is engineered to process raw next-generation sequencing (NGS) data, converting it into interpretable formats such as variant call files (VCF), which provide detailed genetic variant information. This software significantly streamlines the analysis of NGS data for research and clinical purposes. For example, in January 2024, QIAGEN Digital Insights, a US-based bioinformatics entity of QIAGEN, unveiled the QIAGEN CLC Genomics Workbench Premium with LightSpeed technology. This software enhances next-generation sequencing (NGS) for somatic cancer analysis and swiftly processes whole genome sequencing (WGS) samples. Using LightSpeed technology, which efficiently transforms raw FASTQ data into interpretable formats, it can analyze 34x human genomes in 25 minutes and 50x exomes in 90 seconds. With expenses as low as $1 for genomes and a few cents for exomes when utilizing cloud infrastructure, it represents an economical solution for high-throughput laboratories. The program functions on standard hardware or cloud platforms, offering flexibility and exceptional accuracy, making it well-suited for clinical applications while also minimizing its carbon footprint.

Which Organizations Are Involved In The NGS Oncology Market?

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Access The Complete NGS Oncology Market Report:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Holds The Largest Share In The NGS Oncology Market?

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access NGS Oncology Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=24337&type=smp

Browse Through More Reports Similar to the Global NGS Oncology Market 2026, By The Business Research Company

Ngs Based Rna Sequencing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report

Prenatal Dna Sequencing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Next Generation Firewall Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-firewall-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795